Citadel Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-130,800
| Closed | -$1.63M | – | 8516 |
|
|
2016
Q4 | $1.63M | Buy |
130,800
+21,900
| +20% | +$264K | ﹤0.01% | 3199 |
|
|
2016
Q3 | $1.49M | Buy |
108,900
+32,300
| +42% | +$324K | ﹤0.01% | 3313 |
|
|
2016
Q2 | $566K | Buy |
76,600
+18,900
| +33% | +$142K | ﹤0.01% | 4318 |
|
|
2016
Q1 | $369K | Sell |
57,700
-12,100
| -17% | -$67.8K | ﹤0.01% | 4824 |
|
|
2015
Q4 | $436K | Sell |
69,800
-4,600
| -6% | -$30.2K | ﹤0.01% | 4652 |
|
|
2015
Q3 | $434K | Sell |
74,400
-65,300
| -47% | -$503K | ﹤0.01% | 5003 |
|
|
2015
Q2 | $1.16M | Buy |
139,700
+47,400
| +51% | +$419K | ﹤0.01% | 3769 |
|
|
2015
Q1 | $761K | Sell |
92,300
-33,400
| -27% | -$247K | ﹤0.01% | 4309 |
|
|
2014
Q4 | $864K | Buy |
125,700
+42,700
| +51% | +$267K | ﹤0.01% | 3944 |
|
|
2014
Q3 | $448K | Sell |
83,000
-10,000
| -11% | -$58.4K | ﹤0.01% | 4769 |
|
|
2014
Q2 | $592K | Sell |
93,000
-27,700
| -23% | -$190K | ﹤0.01% | 4168 |
|
|
2014
Q1 | $973K | Sell |
120,700
-262,700
| -69% | -$2.05M | ﹤0.01% | 3463 |
|
|
2013
Q4 | $2.62M | Buy |
383,400
+171,300
| +81% | +$925K | ﹤0.01% | 2272 |
|
|
2013
Q3 | $3.9M | Buy |
212,100
+92,500
| +77% | +$1.8M | 0.01% | 1778 |
|
|
2013
Q2 | $2.09M | Buy |
+119,600
| New | +$2.12M | ﹤0.01% | 2452 |
|
Other funds holding ARIA
Citadel Advisors's ARIA Position: Q1 2017 in Review
Citadel Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 180,772 shares — an estimated $2.25M sold.
Citadel Advisors first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $5.77M in Q1 2014. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Citadel Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Citadel Advisors sold 180,772 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $2.25M.
- Citadel Advisors first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Citadel Advisors's Ariad Pharmaceuticals Inc position peaked at $5.77M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.